A biotech startup with roots in Palo Alto, CA has raised $18 million in venture cash to open up a second mid-stage study of its lead therapy, looking to shape a reputation for itself in the lightly populated R&D world of reproductive medicine.
The Column Group has been a busy venture player in the biotech world. And the VC plans to stay busy. In a recent filing at the FDA, the venture group revealed that it has raised close to $176 million out of a planned $250 million fund.
Parisian biotech AAVLife has come out of stealth with a Versant Ventures-led $12 million A round, looking to advance a gene-deleting therapy that promises to treat the rare and deadly Friedreich's ataxia.
An Australian biotech company with a mid-stage pain drug is using a new $45 million venture round from a group that includes a pair of marquee international investors to put down U.S. roots in Stamford, CT, as it pushes ahead in the clinic. The Series C brings Spinifex Pharmaceuticals' total raise to $70 million, says CEO Tom McCarthy, with enough money committed to fund operations for the next three years.
After a record-setting first quarter put billions in the pockets of drug developers, second class of biotech upstarts is scrambling to cash out on Wall Street before an increasingly shaky market shuts the door on life sciences IPOs.
Adamas Pharmaceuticals had to price its IPO at the low end of the range today, then saw the stock price surge in early trading. But the lingering damage of a failed Phase IIb study could be seen when Cerulean stumbled onto the IPO stage after cutting its share price to a mere $7, well below the $11 to $13 range that had been hoped for.
With seed funding from Atlas Venture and an early-stage partnership with Roche, startup Spero Therapeutics is striking out with a novel approach to drug-resistant bacteria amid an antibiotic sea change in the industry.
Even after out-licensing a pair of hepatitis C therapeutic candidates to Vertex, which was bidding on finding a contender as a new wave of transformational drugs approached the market, South San Francisco-based Alios BioPharma stubbornly maintained a very low profile.
Deerfield Management, one of the busiest institutional players in the biotech scene, has rounded up $1.6 billion to back a new wave of biopharma companies, a major niche for this big healthcare gambler.
Cambridge, MA's Neurovance has reeled in a $6.3 million extension to its earlier Series A, money it'll use to push forward with a promising nonstimulant treatment for attention deficit hyperactivity disorder.